Evidence map›Paper›PMID 35455727›Full record

ArticleJournal of personalized medicine2022

Change of Optical Coherence Tomography Morphology and Associated Structural Outcome in Diabetic Macular Edema after Ranibizumab Treatment.

Nan-Ni Chen, Chien-Hsiung Lai, Chai-Yi Lee, Chien-Neng Kuo, Ching-Lung Chen, Jou-Chen Huang, Pei-Chen Wu, Pei-Lun Wu, Chau-Yin Chen

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. The Challenges and Therapeutic Prospects in Eye Disease.Journal of personalized medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nan-Ni ChenDepartment of Ophthalmology, Chang Gung Memorial Hospital, Chiayi 61363, Taiwan.ORCID 0000-0002-1577-4012
Chien-Hsiung LaiDepartment of Ophthalmology, Chang Gung Memorial Hospital, Chiayi 61363, Taiwan.ORCID 0000-0001-8334-4156
Chai-Yi LeeDepartment of Ophthalmology, Show Chwan Hospital, Changhua 50861, Taiwan.ORCID 0000-0002-5719-0488
Chien-Neng KuoDepartment of Ophthalmology, Changhua Christian Hospital, Changhua 50861, Taiwan.
Ching-Lung ChenDepartment of Ophthalmology, Chang Gung Memorial Hospital, Chiayi 61363, Taiwan.
Jou-Chen HuangDepartment of Ophthalmology, Taipei Medical University Hospital, Taipei 110301, Taiwan.
Pei-Chen WuDepartment of Ophthalmology, Landseed International Hospital, Taoyuan 32449, Taiwan.
Pei-Lun WuDepartment of Ophthalmology, Chang Gung Memorial Hospital, Chiayi 61363, Taiwan.
Chau-Yin ChenDepartment of Ophthalmology, Chang Gung Memorial Hospital, Chiayi 61363, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: To investigate the correlation between therapeutic outcome and morphologic changes for diabetic macular edema (DME) after intravitreal injection of ranibizumab (IVIR). (2) Methods: This retrospective study included 228 eyes received IVIR for DME. Each participant was traced for two years after the initial IVIR, while the data of ophthalmic examination, optical coherence tomography (OCT) image, and systemic diseases were collected. The study population was categorized into different subgroups according to the existence of OCT morphologic change and the initial OCT morphologic pattern, including diffuse retinal thickening (DRT), cystoid macular edema (CME), serous retinal detachment (SRD), and vitreomacular interface abnormalities (VMIAs). The primary outcomes were the baseline best-corrected visual acuity (BCVA) and central macular thickness (CMT) during a two-year study period. The distribution of OCT morphologic change and its relation to primary outcome were analyzed. (3) Results: Comparing the 42 eyes (18.4%) with OCT morphological changes to another 186 eyes (81.6%) without such alteration, the former showed a poorer baseline BCVA (0.84 ± 0.39 vs. 0.71 ± 0.36,

Indexed as

antivascular endothelial growth factorsdiabetic macular edemaoptical coherence tomographyvitreomacular interface abnormality

Identifiers

PMID35455727
PMCPMC9027951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.